Cached score snapshot

US.EW · Edwards Lifesciences

110分制 60.4/110;5D動能v2 4/50;排序分 64.4/160

Ranking score 64.4/160
Main score 60.4/110
5D momentum v2 4/50
Rank #189
Setup grade F 27

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 27 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-04 07-20 08-31 09-21 10-09 $79.10$94.00$108.91 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.489 · anchors 120 +1.02% -0.34% / +3.04% 70% 1.3% Actual +0.68% · vs median -0.34% · inside 25-75 band
30D observation +10.19% +1.91% / +14.27% 80% 5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.07% -1.18% / +3.29% 65% 1.9% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-06-04 → 2026-10-09 · 119 archived points · 1 Improving turn signal · 3 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 64.4
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 60.4/110 (觀望)
5D momentum v2 4/50 (弱)
Score with momentum v2 64.4/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 90.7665
ma50 89.3884
close 90.21
prevClose 89.95
avgVolume20 2974885
volumeRatio 0.69
changePercent 0.29

Metrics snapshot

close 90.21
volume 2043700
changePercent 0.29

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 60.4/110
Main rating 觀望
5D momentum v2 4/50
Score with momentum v2 64.4/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.7/5 · 較差

Dimension score 2.7/5
Dimension grade 較差

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0
debtPoints 0.5
marginPoints 0.4
turnoverUsdM 184.3622
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 10/20 · 較差

Dimension score 10/20
Dimension grade 較差

Sub-items

cmfPoints 2.4
mfiPoints 2.4
obvPoints 2.4
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.EW
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 11.4/15 · 良好

Dimension score 11.4/15
Dimension grade 良好

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 14.51

trend

score 3.4

details

qqq

ma20 717.942
ma50 712.064
name QQQ
close 716.43
points 1.4

spy

ma20 769.216
ma50 753.9552
name SPY
close 769.35
points 2
source twelvedata+fred
atrPct 1.8545
atrPoints 4
cciPoints 1.6
vixPoints 2.4
marketTrendPoints 3.4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 4
catalystCount 0
catalystPoints 2

風險管理 — 7.4/10 · 良好

Dimension score 7.4/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 1.8545
turnoverUsdM 184.3622
liquidityPoints 0.4
volatilityPoints 1.2
rrPoints 1.4

stopLevels

symbol US.EW
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 86.8642

strength_details

ma_score 2
atr_score 2.5
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.3
stop_loss_percent 3.7
take_profit_price 94.7205
target_multiplier 1.9
technical_strength 1.55
take_profit_percent 5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.3481
stopLossPercent 3.7089
diversificationPoints 2

技術信號 — 18.9/30 · 一般

Dimension score 18.9/30
Dimension grade 一般

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 3
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 3
vcp_reason 波幅收縮(14.1%→4.9%);量縮(v10/v30=0.69);跌縮量(近10日5日);站上MA50;Ready=Y;Confirm=N

vcp_metrics

up_days 4
vol_ref 3990190
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 2767710
avg_vol_20 3070345
avg_vol_30 3990190
range_pct_10 0.0494
range_pct_20 0.0961
range_pct_30 0.1413
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 0
breakout_20d_ok false
vol_ratio_10_30 0.6936
dist_to_20d_high 0.0394
down_shrink_days 5
breakout_level_20d 93.91
vcp_breakout_confirm false
contraction_ratio_10_30 0.3498
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 2.4
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 0.4

情緒分析 — 8/10 · 優秀

Dimension score 8/10
Dimension grade 優秀

Sub-items

sentiment

score 8

details

source finnhub_news_keyword_model
articleCount 4
negativeHits 0
positiveHits 3
sentimentScoreRaw 1.8

sentimentData

raw {"id":141281699,"url":"https://finnhub.io/api/news?id=fbaa0fb465cb7b5e94846908c161eb264c0d032f7d5847c1fe48539bec4bf65b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...","category":"company","datetime":1787271133,"headline":"Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?"}, {"id":141281712,"url":"https://finnhub.io/api/news?id=7cbf6a4bd23762f011394fe6ea8002bc11c79ee562a732acfa1f89a8c4684880","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...","category":"company","datetime":1787213454,"headline":"Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings"}, {"id":141226765,"url":"https://finnhub.io/api/news?id=944238222c9a941c04cbf9bb360c8aaf00f754e3da0e49ccc10edebf065198f3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.","category":"company","datetime":1786725420,"headline":"Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?"}, {"id":141110261,"url":"https://finnhub.io/api/news?id=4115d1e3ced7ffc938f7e11b62364d19c915c9f89f2113ea724850dd066e3538","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]","category":"company","datetime":1785856652,"headline":"Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match"}
raw_source {"id":141331543,"url":"https://finnhub.io/api/news?id=5ec2d4c75b529299477c3b76fd4b9480a3d4fae681248ea808c3d10437c3ab15","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options.\nWhat Happened: The latest Form 4 filing on","category":"company","datetime":1787828534,"headline":"Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences"}, {"id":141279655,"url":"https://finnhub.io/api/news?id=4022a61f18744248d075fbe3cc8738debb8f01b33118af64b4cac3ad000ade69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.","category":"company","datetime":1787331660,"headline":"Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?"}, {"id":141281699,"url":"https://finnhub.io/api/news?id=fbaa0fb465cb7b5e94846908c161eb264c0d032f7d5847c1fe48539bec4bf65b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...","category":"company","datetime":1787271133,"headline":"Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?"}, {"id":141279658,"url":"https://finnhub.io/api/news?id=ccdd2318d04922d45cc700e03560485e831e0d06bfb5bd3eddc8df398c53b11c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.","category":"company","datetime":1787240760,"headline":"Should Investors Buy STERIS as Growth Meets Reasonable Valuation?"}, {"id":141281711,"url":"https://finnhub.io/api/news?id=33fb2f7d230305748eb64361fcd64ac85f4c63044989f61841a0253cd5a060e9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.","category":"company","datetime":1787240640,"headline":"Should You Hold Edwards Lifesciences Stock in Your Portfolio?"}, {"id":141281712,"url":"https://finnhub.io/api/news?id=7cbf6a4bd23762f011394fe6ea8002bc11c79ee562a732acfa1f89a8c4684880","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...","category":"company","datetime":1787213454,"headline":"Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings"}, {"id":141257577,"url":"https://finnhub.io/api/news?id=59a8c98036ebd53aa47d15b1c10d92f5707d3dbbb713613742e196709dbde0eb","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a market capitalization","category":"company","datetime":1787140833,"headline":"Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years"}, {"id":141265012,"url":"https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...","category":"company","datetime":1787139000,"headline":"HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"}, {"id":141281702,"url":"https://finnhub.io/api/news?id=9ee0f935c15acfa81f3ddf768978842481802bbaccf219995d7b80d62e8f8366","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"As structural heart disease continues to impact a growing number of people across Asia Pacific amid a rapidly ageing population, Edwards Lifesciences (Edwards) brought together patients for its annual Asia-Pacific Patient Experience event. The programme created a platform for patients, caregivers, healthcare professionals and employees to share perspectives, foster meaningful connections and deepen understanding of the patient journey.","category":"company","datetime":1787133600,"headline":"Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care"}, {"id":141251970,"url":"https://finnhub.io/api/news?id=4364ba6127479c07f5699a16fac7cbec7765cc2acfb197a9f0960759f80cbeac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.","category":"company","datetime":1787002200,"headline":"BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire"}, {"id":141226765,"url":"https://finnhub.io/api/news?id=944238222c9a941c04cbf9bb360c8aaf00f754e3da0e49ccc10edebf065198f3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.","category":"company","datetime":1786725420,"headline":"Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?"}, {"id":141219196,"url":"https://finnhub.io/api/news?id=d589796c49ee8c58aad29f907397207bc3d2821e4436174cdabb2cfa8eb12a60","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often","category":"company","datetime":1786714524,"headline":"9 Health Care Stocks Whale Activity In Today’s Session"}, {"id":141216725,"url":"https://finnhub.io/api/news?id=75b3ea82141ce5c2d9b288a912788b857b5a70b3f29d76f59065d6a21564acbb","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1282122168/image_1282122168.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"EW","summary":"Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why it’s a Buy—new launches, insider buying, cost savings.","category":"company","datetime":1786705872,"headline":"Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead"}, {"id":141220590,"url":"https://finnhub.io/api/news?id=6ee2ff0112658e580c4563d0a8c6ffbb026313e5cc042f656138199849bc8dc6","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalization","category":"company","datetime":1786643145,"headline":"$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today"}, {"id":141205611,"url":"https://finnhub.io/api/news?id=dd5eca2ade8f4181ead20a9e255e7c1a5afce1573708bd3d80f4816f41e5a7fe","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.","category":"company","datetime":1786625460,"headline":"Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation"}, {"id":141202085,"url":"https://finnhub.io/api/news?id=8688db89e262b9bd5d93cb3731e971b1f24a8c364cc2fc621a4f9c938d2f806a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.","category":"company","datetime":1786539674,"headline":"Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?"}, {"id":141192888,"url":"https://finnhub.io/api/news?id=8bfe3da79a9d72b2c4f660fa91d74daddc52a60efc7a41079b049140729b94ef","image":"","source":"SeekingAlpha","related":"EW","summary":"","category":"company","datetime":1786528125,"headline":"Edwards Lifesciences: Strong Execution, But Little Room For Error At $90"}, {"id":141191790,"url":"https://finnhub.io/api/news?id=3b4a18b4d28df314a1c8e3ba7b6ed1d79058f97d4fb702b12e7d1f1b737ab971","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182459087/image_1182459087.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"EW","summary":"Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.","category":"company","datetime":1786506905,"headline":"Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else"}, {"id":141137293,"url":"https://finnhub.io/api/news?id=262782447449ff61a7c3702f9cf92ea2613dbee793882d07196dcd81e31db6ba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.","category":"company","datetime":1786030860,"headline":"Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?"}, {"id":141138529,"url":"https://finnhub.io/api/news?id=3d6adcd10fcf2ffa79d180e9fc6d7fcd0af2335aa79abdac4e9592049ff9afa5","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256895141/image_2256895141.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"EW","summary":"For the second quarter of 2026, Aristotle Capital’s Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Read more here.","category":"company","datetime":1786030140,"headline":"Aristotle Value Equity WM Q2 2026 Portfolio Performance"}, {"id":141110261,"url":"https://finnhub.io/api/news?id=4115d1e3ced7ffc938f7e11b62364d19c915c9f89f2113ea724850dd066e3538","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]","category":"company","datetime":1785856652,"headline":"Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match"}
data_source finnhub_news_keyword_model
article_count 4
negative_hits 0
positive_hits 3
recomputed_at_score true
sentiment_score_raw 1.8
source_article_count 21
discarded_article_count 17
sentimentPoints 8

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.7 5/110 54% 2.7
資金流 10 20/110 50% 10
市場環境 11.4 15/110 76% 11.4
催化劑 2 20/110 10% 2
風險管理 7.4 10/110 74% 7.4
技術信號 18.9 30/110 63% 18.9
情緒分析 8 10/110 80% 8

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 4/50
ret_5d 0.0047
max_score 50
max_total 50
raw_total 4
vcp_bonus 0
vol_ratio 0.6656
ret_points 4
vol_points 0
range_ratio 0.4583
volat_points 0
day_range_pct 0.0095
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 0
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 1.8545
turnoverUsdM 184.3622
liquidityPoints 0.4
volatilityPoints 1.2
rrPoints 1.4

stopLevels

symbol US.EW
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 86.8642

strength_details

ma_score 2
atr_score 2.5
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.3
stop_loss_percent 3.7
take_profit_price 94.7205
target_multiplier 1.9
technical_strength 1.55
take_profit_percent 5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.3481
stopLossPercent 3.7089
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.7/5分
資金流分析總分: 10/20分
市場環境分析總分: 11.4/15分
催化劑分析: 2/20分
風險管理總分: 7.4/10分
技術信號分析總分: 18.9/30分
情緒分析: 8/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 1.6729
rule ATR / current price; lower volatility scores higher
score 8
atr_pct 1.85
cci
rule Cursor_18.24 CCI bands
level 弱勢
score 4
value -39.92
cmf
rule Cursor_18.24 CMF bands
level 輕微流入
score 6
value 0.1093
kdj
d 39.52
j 25.15
k 34.73
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 52.85
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 6
trend 有流入
value -6969200
recentSlope 202970
previousSlope 308030
rsi
value 41.5
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 92.8969
position SAR喺價上
distancePct 2.98
previousTrend 下降
ma50
value 89.3884
macd
macd 0.5221
trend 中性偏多
signal 0.7024
histogram -0.1803
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 90.6406
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 空升
ratio 0.69
score 2
avgVolume 2974885
currentVolume 2043700
derived
ma20 90.7665
ma50 89.3884
prevClose 89.95
avgVolume10 2686430
avgVolume20 2974885
changePercent 0.29
avgVolumeForScore 2974885
ma_cross
ma20 90.7665
ma50 89.3884
rule Cursor_18.24 MA20/MA50 cross
cross 接近
score 6
prevMa20 90.5595
prevMa50 89.3178
spreadPct 1.54
isVolumeBreakout false
bollinger
lower 88.0875
upper 93.4455
position 中間
rsi_short
value 58.26
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.69

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 1.854450726083583,
        "turnoverUsdM": 184.362177,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.EW",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 86.8642,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2.5,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.7,
      "take_profit_price": 94.7205,
      "target_multiplier": 1.9,
      "technical_strength": 1.55,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.348108075796521,
    "stopLossPercent": 3.708901452167166,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 64.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 90.7665,
    "ma50": 89.3884,
    "close": 90.21,
    "prevClose": 89.95,
    "avgVolume20": 2974885,
    "volumeRatio": 0.69,
    "changePercent": 0.29
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": 0.0046775810223853576,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.6656255241674796,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.45829484876152726,
      "volat_points": 0,
      "day_range_pct": 0.009533311162842251,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 64.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 54,
        "contribution": 2.7
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 11.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 76,
        "contribution": 11.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 18.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 63,
        "contribution": 18.9
      },
      {
        "raw": 8,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 80,
        "contribution": 8
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 60.4,
    "details": [
      "基本面分析總分: 2.7/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 11.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 18.9/30分",
      "情緒分析: 8/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.7,
      "資金流": 10,
      "市場環境": 11.4,
      "情緒分析": 8,
      "技術信號": 18.9,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 184.362177,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.EW",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.51
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 717.9420018500002,
                "ma50": 712.0640004399997,
                "name": "QQQ",
                "close": 716.42999,
                "points": 1.4
              },
              "spy": {
                "ma20": 769.2159945000001,
                "ma50": 753.9552012599999,
                "name": "SPY",
                "close": 769.34998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.854450726083583,
          "atrPoints": 4,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "sentiment": {
            "score": 8,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 1.8
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141281699,
                "url": "https://finnhub.io/api/news?id=fbaa0fb465cb7b5e94846908c161eb264c0d032f7d5847c1fe48539bec4bf65b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...",
                "category": "company",
                "datetime": 1787271133,
                "headline": "Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?"
              },
              {
                "id": 141281712,
                "url": "https://finnhub.io/api/news?id=7cbf6a4bd23762f011394fe6ea8002bc11c79ee562a732acfa1f89a8c4684880",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...",
                "category": "company",
                "datetime": 1787213454,
                "headline": "Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings"
              },
              {
                "id": 141226765,
                "url": "https://finnhub.io/api/news?id=944238222c9a941c04cbf9bb360c8aaf00f754e3da0e49ccc10edebf065198f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.",
                "category": "company",
                "datetime": 1786725420,
                "headline": "Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?"
              },
              {
                "id": 141110261,
                "url": "https://finnhub.io/api/news?id=4115d1e3ced7ffc938f7e11b62364d19c915c9f89f2113ea724850dd066e3538",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]",
                "category": "company",
                "datetime": 1785856652,
                "headline": "Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match"
              }
            ],
            "raw_source": [
              {
                "id": 141331543,
                "url": "https://finnhub.io/api/news?id=5ec2d4c75b529299477c3b76fd4b9480a3d4fae681248ea808c3d10437c3ab15",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options.\nWhat Happened: The latest Form 4 filing on",
                "category": "company",
                "datetime": 1787828534,
                "headline": "Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences"
              },
              {
                "id": 141279655,
                "url": "https://finnhub.io/api/news?id=4022a61f18744248d075fbe3cc8738debb8f01b33118af64b4cac3ad000ade69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.",
                "category": "company",
                "datetime": 1787331660,
                "headline": "Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?"
              },
              {
                "id": 141281699,
                "url": "https://finnhub.io/api/news?id=fbaa0fb465cb7b5e94846908c161eb264c0d032f7d5847c1fe48539bec4bf65b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...",
                "category": "company",
                "datetime": 1787271133,
                "headline": "Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?"
              },
              {
                "id": 141279658,
                "url": "https://finnhub.io/api/news?id=ccdd2318d04922d45cc700e03560485e831e0d06bfb5bd3eddc8df398c53b11c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.",
                "category": "company",
                "datetime": 1787240760,
                "headline": "Should Investors Buy STERIS as Growth Meets Reasonable Valuation?"
              },
              {
                "id": 141281711,
                "url": "https://finnhub.io/api/news?id=33fb2f7d230305748eb64361fcd64ac85f4c63044989f61841a0253cd5a060e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.",
                "category": "company",
                "datetime": 1787240640,
                "headline": "Should You Hold Edwards Lifesciences Stock in Your Portfolio?"
              },
              {
                "id": 141281712,
                "url": "https://finnhub.io/api/news?id=7cbf6a4bd23762f011394fe6ea8002bc11c79ee562a732acfa1f89a8c4684880",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...",
                "category": "company",
                "datetime": 1787213454,
                "headline": "Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings"
              },
              {
                "id": 141257577,
                "url": "https://finnhub.io/api/news?id=59a8c98036ebd53aa47d15b1c10d92f5707d3dbbb713613742e196709dbde0eb",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a market capitalization",
                "category": "company",
                "datetime": 1787140833,
                "headline": "Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years"
              },
              {
                "id": 141265012,
                "url": "https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...",
                "category": "company",
                "datetime": 1787139000,
                "headline": "HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"
              },
              {
                "id": 141281702,
                "url": "https://finnhub.io/api/news?id=9ee0f935c15acfa81f3ddf768978842481802bbaccf219995d7b80d62e8f8366",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "As structural heart disease continues to impact a growing number of people across Asia Pacific amid a rapidly ageing population, Edwards Lifesciences (Edwards) brought together patients for its annual Asia-Pacific Patient Experience event. The programme created a platform for patients, caregivers, healthcare professionals and employees to share perspectives, foster meaningful connections and deepen understanding of the patient journey.",
                "category": "company",
                "datetime": 1787133600,
                "headline": "Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care"
              },
              {
                "id": 141251970,
                "url": "https://finnhub.io/api/news?id=4364ba6127479c07f5699a16fac7cbec7765cc2acfb197a9f0960759f80cbeac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.",
                "category": "company",
                "datetime": 1787002200,
                "headline": "BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire"
              },
              {
                "id": 141226765,
                "url": "https://finnhub.io/api/news?id=944238222c9a941c04cbf9bb360c8aaf00f754e3da0e49ccc10edebf065198f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.",
                "category": "company",
                "datetime": 1786725420,
                "headline": "Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?"
              },
              {
                "id": 141219196,
                "url": "https://finnhub.io/api/news?id=d589796c49ee8c58aad29f907397207bc3d2821e4436174cdabb2cfa8eb12a60",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1786714524,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141216725,
                "url": "https://finnhub.io/api/news?id=75b3ea82141ce5c2d9b288a912788b857b5a70b3f29d76f59065d6a21564acbb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1282122168/image_1282122168.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why it’s a Buy—new launches, insider buying, cost savings.",
                "category": "company",
                "datetime": 1786705872,
                "headline": "Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead"
              },
              {
                "id": 141220590,
                "url": "https://finnhub.io/api/news?id=6ee2ff0112658e580c4563d0a8c6ffbb026313e5cc042f656138199849bc8dc6",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalization",
                "category": "company",
                "datetime": 1786643145,
                "headline": "$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141205611,
                "url": "https://finnhub.io/api/news?id=dd5eca2ade8f4181ead20a9e255e7c1a5afce1573708bd3d80f4816f41e5a7fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.",
                "category": "company",
                "datetime": 1786625460,
                "headline": "Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation"
              },
              {
                "id": 141202085,
                "url": "https://finnhub.io/api/news?id=8688db89e262b9bd5d93cb3731e971b1f24a8c364cc2fc621a4f9c938d2f806a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.",
                "category": "company",
                "datetime": 1786539674,
                "headline": "Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?"
              },
              {
                "id": 141192888,
                "url": "https://finnhub.io/api/news?id=8bfe3da79a9d72b2c4f660fa91d74daddc52a60efc7a41079b049140729b94ef",
                "image": "",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "",
                "category": "company",
                "datetime": 1786528125,
                "headline": "Edwards Lifesciences: Strong Execution, But Little Room For Error At $90"
              },
              {
                "id": 141191790,
                "url": "https://finnhub.io/api/news?id=3b4a18b4d28df314a1c8e3ba7b6ed1d79058f97d4fb702b12e7d1f1b737ab971",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182459087/image_1182459087.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.",
                "category": "company",
                "datetime": 1786506905,
                "headline": "Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else"
              },
              {
                "id": 141137293,
                "url": "https://finnhub.io/api/news?id=262782447449ff61a7c3702f9cf92ea2613dbee793882d07196dcd81e31db6ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.",
                "category": "company",
                "datetime": 1786030860,
                "headline": "Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?"
              },
              {
                "id": 141138529,
                "url": "https://finnhub.io/api/news?id=3d6adcd10fcf2ffa79d180e9fc6d7fcd0af2335aa79abdac4e9592049ff9afa5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256895141/image_2256895141.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "For the second quarter of 2026, Aristotle Capital’s Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Read more here.",
                "category": "company",
                "datetime": 1786030140,
                "headline": "Aristotle Value Equity WM Q2 2026 Portfolio Performance"
              },
              {
                "id": 141110261,
                "url": "https://finnhub.io/api/news?id=4115d1e3ced7ffc938f7e11b62364d19c915c9f89f2113ea724850dd066e3538",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]",
                "category": "company",
                "datetime": 1785856652,
                "headline": "Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 4,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.8,
            "source_article_count": 21,
            "discarded_article_count": 17
          },
          "sentimentPoints": 8
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.9,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 3,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 3,
            "vcp_reason": "波幅收縮(14.1%→4.9%);量縮(v10/v30=0.69);跌縮量(近10日5日);站上MA50;Ready=Y;Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 3990190,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 2767710,
              "avg_vol_20": 3070345,
              "avg_vol_30": 3990190,
              "range_pct_10": 0.0494401951003214,
              "range_pct_20": 0.0961090788160958,
              "range_pct_30": 0.14133688061190555,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.6936286242008526,
              "dist_to_20d_high": 0.039399424981365165,
              "down_shrink_days": 5,
              "breakout_level_20d": 93.91,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.34980392156862694
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 1.854450726083583,
              "turnoverUsdM": 184.362177,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.EW",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 86.8642,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2.5,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.7,
            "take_profit_price": 94.7205,
            "target_multiplier": 1.9,
            "technical_strength": 1.55,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.348108075796521,
          "stopLossPercent": 3.708901452167166,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 1.6729,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.85
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -39.92
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1093
    },
    "kdj": {
      "d": 39.52,
      "j": 25.15,
      "k": 34.73,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 52.85
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": -6969200,
      "recentSlope": 202970,
      "previousSlope": 308030
    },
    "rsi": 41.5,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 92.8969,
      "position": "SAR喺價上",
      "distancePct": 2.98,
      "previousTrend": "下降"
    },
    "ma50": 89.3884,
    "macd": {
      "macd": 0.5221389201669098,
      "trend": "中性偏多",
      "signal": 0.7024001040357184,
      "histogram": -0.18026118386880863
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 90.6406,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.69,
      "score": 2,
      "avgVolume": 2974885,
      "currentVolume": 2043700
    },
    "derived": {
      "ma20": 90.7665,
      "ma50": 89.3884,
      "prevClose": 89.95,
      "avgVolume10": 2686430,
      "avgVolume20": 2974885,
      "changePercent": 0.29,
      "avgVolumeForScore": 2974885
    },
    "ma_cross": {
      "ma20": 90.7665,
      "ma50": 89.3884,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 90.5595,
      "prevMa50": 89.3178,
      "spreadPct": 1.54,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 88.0875,
      "upper": 93.4455,
      "position": "中間"
    },
    "rsi_short": 58.26,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.69
    }
  }
}

Raw metrics JSON

{
  "close": 90.21,
  "volume": 2043700,
  "changePercent": 0.29
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.